Individualized cancer vaccines and antibody-drug conjugates will be among the dominant biotech innovations in cancer next ...
On Friday, DexCom Inc (DXCM) stock saw a decline, ending the day at $80.24 which represents a decrease of $-0.33 or -0.41% from the prior close of $80.57. The stock opened at $80.03 and touched a low ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback